Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022104 (
irritable bowel syndrome
)
8,033
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A cross-sectional home survey on drug use, mental health, somatic illnesses and psychosocial issues was carried out with a nation-wide multi-stage probability sample of 4,292 persons aged 12-17, 18-24 and 25-64. This article aims at investigating the relationship of specific categories of somatic illnesses with a psychological component to the use of licit and illicit drugs. For the purpose of analysis the total sample was divided into three mutually exclusive groups: group A included respondents who have reported illicit drug use 1-3 or more times in their lives; group B comprised respondents who have reported the use of licit psychotropic drugs 3 or more times in their lives; group C included non-user respondents. A higher proportion of respondents of groups A and B of both sexes in all three age strata reported the presence of a specific somatic illness such as bronchial
asthma
, essential hypertension, peptic ulcer,
irritable bowel syndrome
, rheumatoid arthritis, dermatitis or eczema, in comparison to group C (non-user) respondents. This difference was greater in the adolescent group 12-17 years of age. Possible explanations of the association between somatic illness with a psychological component and drug use are discussed.
...
PMID:Drug use and somatic illnesses with psychological component: a nation-wide survey among adolescents and adults in Greece. 827 76
Tachykinins belong to an evolutionarily conserved family of peptide neurotransmitters. The mammalian tachykinins include substance P, neurokinin A and neurokinin B, which exert their effects by binding to specific receptors. These tachykinin receptors are divided into three types, designated NK1, NK2 and NK3, respectively. Tachykinin receptors have been cloned and contain seven segments spanning the cell membrane, indicating their inclusion in the G-protein-linked receptor family. The continued development of selective agonists and antagonists for each receptor has helped elucidate roles for these mediators, ranging from effects in the central nervous system to the perpetuation of the inflammatory response in the periphery. Various selective ligands have shown both inter- and intraspecies differences in binding potencies, indicating distinct binding sites in the tachykinin receptor. The interaction of tachykinin with its receptor activates Gq, which in turn activates phospholipase C to break down phosphatidyl inositol bisphosphate into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 acts on specific receptors in the sarcoplasmic reticulum to release intracellular stores of Ca2+, while DAG acts via protein kinase C to open L-type calcium channels in the plasma membrane. The rise in intracellular [Ca2+] induces the tissue response. With an array of actions as diverse as that seen with tachykinins, there is scope for numerous therapeutic possibilities. With the development of potent, selective non-peptide antagonists, there could be potential benefits in the treatment of a variety of clinical conditions, including chronic pain, Parkinson's disease, Alzheimer's disease, depression, rheumatoid arthritis,
irritable bowel syndrome
and
asthma
.
...
PMID:Tachykinins: receptor to effector. 892 4
Plasma cortisol, blood glucose, serum lipids and lipoproteins were estimated in diseased human subjects and normal control volunteers. Serum triglyceride (Tg) total cholesterol (Tc) and cholesterol content of very low density lipoprotein (VLDLc), low density lipoprotein (LDLc) and high density lipoprotein (HDLc) were assayed under lipid profile. Clinical investigations were carried out on 115 subjects which involved 30 control, 25
irritable bowel syndrome
(
IBS
), 30 bronchial
asthma
and 30 rheumatoid arthritis patients. The results of this preliminary study showed a significant change in the levels of all the biochemical parameters in diseased subjects in comparison with controls. Increased levels of atherogenic lipids, Tg, VLDLc and LDLc were found in rheumatoid arthritis subjects. This suggests that arthritis subjects are relatively at higher risk of developing coronary heart disease. Furthermore hypercholesterolemia may aggravate the risk condition in arthritis patients by artereosclerosis. The significant elevation in the levels of plasma cortisol reveals the fact that rheumatoid arthritis is a stabilized and chronic psychosomatic disorder, since, homeostatic competence is disrupted following decline in the tendency of stress-response to return to normalcy.
...
PMID:A study on physiological changes in certain psychosomatic disorders with reference to cortisol, blood glucose and lipid profile. 906 10
Exacerbation of certain medical conditions at specific phases of the menstrual cycle is a well-recognized phenomenon. We review the effects of the menstrual cycle on medical conditions, including menstrual migraine, epilepsy,
asthma
, rheumatoid arthritis,
irritable bowel syndrome
, and diabetes. We discuss the role of medical suppression of ovulation using gonadotropin-releasing hormone agonists in the evaluation and treatment of these disorders. Peer-reviewed publications from English-language literature were located via MEDLINE or from bibliographies of relevant articles. We reviewed all review articles, case reports and series, and therapeutic trials. Emphasis was placed on diagnosis and therapy of menstrual cycle-related exacerbations of disease processes. Abrupt changes in the concentrations of circulating ovarian steroids at ovulation and premenstrually may account for menstrual cycle-related changes in these chronic conditions. Accurate documentation of symptoms on a menstrual calendar allows identification of women with cyclic alterations in disease activity. Medical suppression of ovulation using gonadotropin-releasing hormone agonists can be useful for both diagnosis and treatment of any severe, recurrent menstrual cycle-related disease exacerbations.
...
PMID:Effects of the menstrual cycle on medical disorders. 966 48
In recent years it has become apparent that the oxidation of lipids, or lipid peroxidation, is a crucial step in the pathogenesis of several disease states in adult and infant patients. Lipid peroxidation is a process generated naturally in small amounts in the body, mainly by the effect of several reactive oxygen species (hydroxyl radical, hydrogen peroxide etc.). It can also be generated by the action of several phagocytes. These reactive oxygen species readily attack the polyunsaturated fatty acids of the fatty acid membrane, initiating a self-propagating chain reaction. The destruction of membrane lipids and the end-products of such lipid peroxidation reactions are especially dangerous for the viability of cells, even tissues. Enzymatic (catalase, superoxide dismutasse) and nonenzymatic (vitamins A and E) natural antioxidant defence mechanisms exist; however, these mechanisms may be overcome, causing lipid peroxidation to take place. Since lipid peroxidation is a self-propagating chain-reaction, the initial oxidation of only a few lipid molecules can result in significant tissue damage. Despite extensive research in the field of lipid peroxidation it has not yet been precisely determined if it is the cause or an effect of several pathological conditions. Lipid peroxidation has been implicated in disease states such as atherosclerosis,
IBD
, ROP, BPD,
asthma
, Parkinson's disease, kidney damage, preeclampsia and others.
...
PMID:Lipid peroxidation and tissue damage. 1045 7
The observations that
irritable bowel syndrome
(
IBS
) may be precipitated by an acute enteric infection, or occurs commonly in patients in remission from inflammatory bowel disease (IBD) has prompted consideration of inflammation as a putative basis for symptom generation in
IBS
. In this regard,
IBS
may follow a pattern of pathogenesis that is similar to
asthma
--which was once considered a psychosomatic disease. This review examines the basic scientific evidence of a functional interface between the immune and sensory-motor systems of the gut and discusses how this may be relevant to a subgroup of
IBS
patients. In addition, review will examine the implications of this for the diagnosis and treatment of
IBS
.
...
PMID:Putative inflammatory and immunological mechanisms in functional bowel disorders. 1058 Sep 19
The classical Chinese pharmacopoeia describes a large number of herbal formulations that are used for the treatment of a wide variety of diseases. This therapeutic approach is ignored by many and considered to be an alternative to conventional medicine by others. The scientific proof and clinical validation of these herbal formulations require a rigorous approach that includes chemical standardization, biological assays, animal models, and clinical trials. Such Western methodologies need to take into consideration the complex mixture of chemicals and how they are to be used in humans. This review examines relevant studies on the use of traditional Chinese medicines for the treatment of such diseases as bronchial
asthma
, atopic dermatitis, and
irritable bowel syndrome
. An interdisciplinary approach to traditional Chinese medicine may provide a platform for the discovery of novel therapeutics composed of multiple chemical compounds.
...
PMID:Traditional Chinese medicine: an approach to scientific proof and clinical validation. 1079 14
Tachykinins mediate a variety of physiological processes in the gastrointestinal, pulmonary and genito-urinary tract mainly through the stimulation of NK1 and NK2 receptors. Preclinical evidence obtained through the use of selective tachykinin receptor antagonists indicates that endogenous tachykinins are involved in augmented smooth muscle contraction, vasodilatation, chemotaxis and activation of immune cells, mucus secretion, water absorption/secretion. Recent evidence also suggests that endogenous tachykinins released at the peripheral level may play a role in visceral inflammation, hyperreflexia and hyperalgesia. Possible mechanisms underlying the stimulation of primary afferent neurons by tachykinins may involve a direct excitation of these neurons and the release of mediators which sensitise or stimulate sensory nerves. Tachykinin receptor antagonists could have a clinical utility in several human diseases such as
irritable bowel syndrome
,
asthma
, and in micturition disturbances characterized by a hyperactive bladder.
...
PMID:Peripheral actions of tachykinins. 1104 34
Menstrual cycle-related exacerbation of common medical conditions such as migraine, epilepsy,
asthma
,
irritable bowel syndrome
, and diabetes, is a well-recognized phenomenon. Accurate documentation of symptoms on a menstrual calendar allows identification of women with cyclic alterations in disease activity.
...
PMID:Menstrual cycle effects on common medical conditions. 1128 Aug 58
Tachykinins are widely distributed in the peripheral nervous system of the respiratory, urinary and gastrointestinal tract, stored in enteric neurons and in peripheral nerve endings of capsaicin-sensitive primary afferent neurons from which are released by stimuli having both pathological and physiological relevance. The most studied effects produced by tachykinins in these systems are smooth muscle contraction, plasma protein extravasation, mucus secretion and recruitment/activation of immune cells. The use of tachykinin receptor-selective antagonists and knockout animals has enabled to identify the involvement of tachykinin NK(1), NK(2) and NK(3) receptors as mediators of peripheral effects of tachykinins in different systems/species. The bulk of data obtained in experimental animal models suggests that tachykinins could contribute to the genesis of symptoms accompanying various human diseases including
asthma
/bronchial hyperreactivity, cystitis of various aetiology, inflammatory bowel diseases and
irritable bowel syndrome
. Tachykinin receptor antagonists are expected to afford therapeutically relevant effects.
...
PMID:Peripheral tachykinin receptors as targets for new drugs. 1169 23
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>